IL1B — Interleukin-1 Beta

Overview

Interleukin-1 beta (IL-1β) is a potent pro-inflammatory cytokine that serves as a master regulator of neuroinflammation in the central nervous system. Produced primarily by microglia, astrocytes, and infiltrating immune cells, IL-1β drives a cascade of inflammatory responses that contribute to the pathogenesis of Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and other neurodegenerative conditions 1. The cytokine is encoded by the IL1B gene on chromosome 2q14.1 and is synthesized as an inactive propeptide (pro-IL-1β) that requires proteolytic cleavage by caspase-1 within the NLRP3 inflammasome complex to become biologically active.

Pathway Diagram

flowchart TD
    IL1B["IL1B"]
    style IL1B fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0
    Inflammation["Inflammation"]
    IL1B -->|"activates"| Inflammation
    inflammatory_diseases["inflammatory diseases"]
    IL1B -->|"causes"| inflammatory_diseases
    Autophagy["Autophagy"]
    IL1B -->|"activates"| Autophagy
    Als["Als"]
    IL1B -->|"activates"| Als
    Myeloid_Cell_Immune_Response["Myeloid Cell Immune Response"]
    IL1B -->|"mediates"| Myeloid_Cell_Immune_Response
    Infection["Infection"]
    IL1B -->|"activates"| Infection
    Neuroinflammation["Neuroinflammation"]
    IL1B -->|"involved in"| Neuroinflammation
    Osteoclast_Differentiation["Osteoclast Differentiation"]
    IL1B -->|"regulates"| Osteoclast_Differentiation
    h_e7e1f943["h-e7e1f943"]
    h_e7e1f943 -->|"therapeutic target"| IL1B
    INFLAMMASOME_COMPLEX["INFLAMMASOME COMPLEX"]
    INFLAMMASOME_COMPLEX -->|"associated with"| IL1B
    h_e7e1f943 -->|"targets gene"| IL1B
    TNF["TNF"]
    TNF -->|"activates"| IL1B
    CASP1["CASP1"]
    CASP1 -->|"activates"| IL1B
    NLRP3_Inflammasome["NLRP3 Inflammasome"]
    NLRP3_Inflammasome -->|"activates"| IL1B
    h_e7e1f943 -->|"targets"| IL1B
    CCL3["CCL3"]
    CCL3 -->|"upregulates"| IL1B
    style Inflammation fill:#ef5350,stroke:#ef5350,color:#e0e0e0
    style inflammatory_diseases fill:#ef5350,stroke:#ef5350,color:#e0e0e0
    style Autophagy fill:#5d4400,stroke:#ffd54f,color:#e0e0e0
    style Als fill:#ef5350,stroke:#ef5350,color:#e0e0e0
    style Myeloid_Cell_Immune_Response fill:#006494,stroke:#888,color:#e0e0e0
    style Infection fill:#ef5350,stroke:#ef5350,color:#e0e0e0
    style Neuroinflammation fill:#006494,stroke:#888,color:#e0e0e0
    style Osteoclast_Differentiation fill:#006494,stroke:#888,color:#e0e0e0
    style h_e7e1f943 fill:#006494,stroke:#888,color:#e0e0e0
    style INFLAMMASOME_COMPLEX fill:#4a1a6b,stroke:#ce93d8,color:#e0e0e0
    style TNF fill:#1b5e20,stroke:#81c784,color:#e0e0e0
    style CASP1 fill:#006494,stroke:#888,color:#e0e0e0
    style NLRP3_Inflammasome fill:#006494,stroke:#888,color:#e0e0e0
    style CCL3 fill:#1b5e20,stroke:#81c784,color:#e0e0e0

Protein Infobox

Molecular Biology and Processing

Gene Structure and Regulation

The IL1B gene spans approximately 9.5 kb and consists of 7 exons. Expression is tightly regulated at multiple levels:

• Transcriptional Control: NF-κB and AP-1 binding sites in the IL1B promoter drive transcription in response to pathogen-associated molecular patterns (PAMPs), damage-associated molecular patterns (DAMPs), and other inflammatory signals

• Post-transcriptional Regulation: mRNA stability elements and microRNA binding (e.g., miR-155) modulate IL1B mRNA half-life

• Epigenetic Control: DNA methylation and histone modifications influence IL1B expression in different cell types

Protein Processing and Maturation

IL-1β is synthesized as a 31 kDa propeptide (pro-IL-1β, amino acids 1-269) that lacks biological activity. Activation requires proteolytic cleavage:

1. Inflammasome Assembly: Pattern recognition receptors (e.g., NLRP3) detect cellular stress signals and assemble the inflammasome complex containing procaspase-1

2. Caspase-1 Activation: Autocatalysis converts procaspase-1 to active caspase-1

3. Pro-IL-1β Cleavage: Caspase-1 cleaves pro-IL-1β between Asp116 and Ala117, releasing the 17 kDa active fragment (amino acids 117-269)

4. Secretion: The active IL-1β is secreted via gasdermin D pores or alternative pathways

Receptor Binding and Signaling

IL-1β signals through the IL-1 receptor complex:

• IL-1 Receptor Type I (IL-1R1): The signaling receptor, requiring the IL-1 receptor accessory protein (IL-1RAP) for signal transduction

• IL-1 Receptor Type II (IL-1R2): A decoy receptor that sequesters IL-1β and prevents signaling

• IL-1 Receptor Antagonist (IL-1RA): A natural antagonist that blocks IL-1R1 binding

Upon binding, the IL-1R1/IL-1RAP complex activates:

1. MyD88-dependent signaling: Adaptor protein MyD88 recruits IRAK kinases

2. NF-κB activation: TRAF6 ubiquitination leads to IKK complex activation and IκB degradation

3. MAPK activation: JNK, p38, and ERK pathways are also activated

4. Gene transcription: Pro-inflammatory genes including IL6, TNF, and itself are expressed

Normal Physiological Function

CNS Homeostasis

Under normal conditions, IL-1β plays essential roles in brain function:

• Synaptic Plasticity: Low-level IL-1β signaling supports long-term potentiation (LTP) and memory formation

• Sleep Regulation: IL-1β participates in sleep-wake cycles and sleep homeostasis

• Neurogenesis: Modulates neural progenitor cell proliferation and differentiation

• Thermoregulation: Contributes to fever responses during infection

Immune Surveillance

The cytokine maintains CNS immune vigilance:

• Microglial Activation: Baseline IL-1β maintains microglial surveillance state

• Response to Injury: Rapidly upregulated following CNS injury or infection

• Host Defense: Essential for protective inflammatory responses to pathogens

Role in Neurodegenerative Diseases

Alzheimer’s Disease

IL-1β is centrally implicated in AD pathogenesis through multiple mechanisms 2:

Amyloid Pathology

• Plaque Association: IL-1β colocalizes with amyloid-beta plaques in AD brain tissue

• APP Processing: IL-1β signaling increases amyloid precursor protein (APP) processing and Aβ production via NF-κB

• Aggregation Modulation: IL-1β affects Aβ aggregation kinetics and plaque formation

• NLRP3 Inflammasome: Aβ activates NLRP3, creating a feed-forward loop of IL-1β production 6

Tau Pathology 3

• Kinase Activation: IL-1β activates GSK3β and CDK5, key tau kinases

• Phosphorylation: Promotes tau phosphorylation at multiple AD-relevant sites (Ser396, Thr231, AT8)

• Tangle Formation: Facilitates tau aggregation and neurofibrillary tangle formation

• Spread Propagation: May contribute to tau pathology propagation between brain regions

Synaptic Dysfunction 9

• Synaptic Pruning: IL-1β promotes excessive microglial phagocytosis of synapses

• LTP Impairment: Chronic IL-1β exposure disrupts long-term potentiation

• Dendritic Spine Loss: Reduces dendritic spine density on hippocampal neurons

• Memory Deficits: IL-1β overexpression in hippocampus impairs spatial memory

Neuroinflammation 11

• Microglial Activation: Sustains chronic microglial activation (" microglia)

• Cytokine Cascade: Triggers production of other pro-inflammatory cytokines (IL-6, TNF-α)

• Blood-Brain Barrier: Compromises BBB integrity, allowing peripheral immune cell infiltration

Parkinson’s Disease

IL-1β contributes to PD through multiple mechanisms 15:

• Dopaminergic Neuron Loss: IL-1β is toxic to substantia nigra dopaminergic neurons

• Microglial Activation: Chronic activation of nigral microglia by IL-1β

• Inflammasome Activation: NLRP3 inflammasome in PD microglia produces IL-1β

• α-Synuclein Interplay: IL-1β accelerates α-synuclein aggregation and propagation

• Neuroinflammation: Elevated IL-1β in substantia nigra, CSF, and blood of PD patients

Amyotrophic Lateral Sclerosis 13

• Motor Neuron Toxicity: IL-1β directly damages upper and lower motor neurons

• Microglial Activation: Sustained neuroinflammatory response in spinal cord

• Disease Progression: IL-1β levels correlate with disease progression rate

• Therapeutic Target: IL-1R1 antagonists show promise in preclinical models

Multiple Sclerosis 14

• Demyelination: IL-1β promotes oligodendrocyte death and demyelination

• Blood-Brain Barrier Breakdown: Facilitates leukocyte infiltration into CNS

• T-cell Activation: Supports Th1 and Th17 responses

• Disease Progression: IL-1β blockade reduces disease activity in MS models

Frontotemporal Dementia

• Tau Pathology: IL-1β contributes to tau phosphorylation and aggregation

• Neuroinflammation: Similar microglial activation patterns as AD

• Behavioral Symptoms: Cytokine-induced changes in frontal cortex function

Therapeutic Targeting

IL-1 Targeting Strategies 10

Approved Biological Agents

1. Anakinra (Kineret): Recombinant IL-1RA; FDA-approved for rheumatoid arthritis

2. Canakinumab (Ilaris): Anti-IL-1β monoclonal antibody; approved for periodic fever syndromes

3. Rilonacept (Arcalyst): IL-1R-Fc fusion protein; traps IL-1β and IL-1α

Clinical Trials in Neurodegeneration

• AD Trials: Canakinumab failed in Phase 3 AD trial (CANTOS sub-study)

• PD Trials: Anakinra in early-phase PD trials (safety established, efficacy unclear)

• ALS Trials: IL-1 blockade showing mixed results in Phase 2

Experimental Approaches

• NLRP3 Inhibitors: Targeting upstream inflammasome activation 6

• Small Molecule IL-1R1 Antagonists: Blood-brain barrier penetrant compounds

• Gene Therapy: AAV-delivered IL-1RA or IL-1R1 decoy

• MicroRNA-based: miR-155 antagonists to reduce IL-1β production

Biomarker Potential

• CSF IL-1β: Elevated in AD, PD, and MS; potential diagnostic aid

• Blood IL-1β: Peripheral biomarker candidate (limited CNS specificity)

• PET Inflammation: IL-1R1 imaging for neuroinflammation visualization

Protein-Protein Interactions

Signaling Complex

• IL-1R1: Primary signaling receptor

• IL-1RAP: Accessory protein required for signaling

• MyD88: Downstream adaptor protein

• IRAK1/4: Kinase cascade members

• TRAF6: E3 ubiquitin ligase

Inflammasome Components

• NLRP3: Pattern recognition receptor forming inflammasome

• ASC: Adaptor protein linking NLRP3 to caspase-1

• Pro-caspase-1: Zymogen for caspase-1 activation

• Gasdermin D: Pore-forming protein for IL-1β secretion

Anti-inflammatory Interactors

• IL-1RA: Natural antagonist

• IL-1R2: Decoy receptor

• SIGIRR: Single Ig IL-1R-related molecule (negative regulator)

Animal Models

Research Directions

Unresolved Questions

1. What triggers chronic IL-1β elevation in neurodegenerative disease?

2. Is IL-1β cause or consequence of neurodegeneration?

3. Can selective CNS IL-1β targeting avoid peripheral immunosuppression?

4. What determines patient response to IL-1 blockade?

Emerging Research

• Single-cell analysis: IL-1β production by specific microglial subsets

• Inflammasome imaging: PET ligands for NLRP3 visualization

• Personalized medicine: IL1B genetic variants affecting treatment response

• Combination therapy: IL-1 targeting with disease-modifying agents

Cross-Links

Related Proteins

• NLRP3 Protein — Inflammasome component

• Caspase-1 Protein — IL-1β activating enzyme

• TNF-α Protein — Related inflammatory cytokine

• IL-6 Protein — Pro-inflammatory cytokine

Related Genes

• IL1B Gene — IL-1 beta gene

• IL1R1 Gene — IL-1 receptor type I

• IL1RA Gene — IL-1 receptor antagonist

Related Mechanisms

• NLRP3 Inflammasome — IL-1β activation pathway

• Neuroinflammation in AD — AD-specific inflammation

• Microglial Activation — CNS immune cells

Related Diseases

• Alzheimer’s Disease — Primary IL-1β target

• Parkinson’s Disease — IL-1β in PD

• Amyotrophic Lateral Sclerosis — IL-1β in ALS

• Multiple Sclerosis — IL-1β in MS